Traditional HF therapies (β-blockers, renin–angiotensin system [RAS] inhibitors) provide indirect benefits by reducing chronic adrenergic and hemodynamic stress, but newer approaches seek a more direct modulation of the cardiac Ca2+ handling machinery. This evidence concerns the gene REN and hydrops fetalis.